Comparing stroke prevention therapy of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: a nationwide retrospective observational study

Table 3 Results of joint DOAC vs. VKA

Events	Incidence rate per 1000 PY		Adjusted HR (95% CI)	p value
Events	VKA	DOAC	Adjusted HR (95% CI)	p value
Stroke	26.69	33.45	1.32 (1.29–1.35)	< .001
TIA	11.16	11.71	1.10 (1.06–1.14)	< .001
Embolism (systemic)	4.01	2.99	0.78 (0.73–0.83)	< .001
Bleeding	136.57	117.7	0.89 (0.88–0.90)	< .001
Mortality (all cause)	61.36	73.5	–	–

VKA vitamin K antagonist, DOAC direct oral anticoagulant, TIA transient ischemic attack, PY person years, HR hazard ratio, CI confidence interval

ISSN: 1741-7015